Neuphoria Therapeutics (NEUP) to Release Earnings on Tuesday

Neuphoria Therapeutics (NASDAQ:NEUP) is expected to issue its results before the market opens on Tuesday, May 19th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.

Neuphoria Therapeutics (NASDAQ:NEUP) last announced its quarterly earnings data on Tuesday, February 17th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.21). On average, analysts expect Neuphoria Therapeutics to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Neuphoria Therapeutics Stock Performance

Shares of NEUP stock opened at $5.17 on Tuesday. The stock’s 50-day moving average is $4.67 and its two-hundred day moving average is $4.38. Neuphoria Therapeutics has a 1 year low of $3.64 and a 1 year high of $21.40. The firm has a market cap of $27.87 million, a price-to-earnings ratio of -1.17 and a beta of 0.72.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Diadema Partners LP grew its holdings in shares of Neuphoria Therapeutics by 133.1% during the fourth quarter. Diadema Partners LP now owns 50,000 shares of the company’s stock worth $194,000 after buying an additional 28,548 shares in the last quarter. Ikarian Capital LLC purchased a new stake in shares of Neuphoria Therapeutics in the fourth quarter valued at $184,000. ADAR1 Capital Management LLC acquired a new stake in Neuphoria Therapeutics in the 4th quarter worth about $116,000. Millennium Management LLC purchased a new position in shares of Neuphoria Therapeutics during the 3rd quarter worth about $216,000. Finally, Geode Capital Management LLC increased its position in Neuphoria Therapeutics by 33.3% during the fourth quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock worth $67,000 after purchasing an additional 4,325 shares during the last quarter. 15.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on NEUP. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Thursday, January 22nd. Zacks Research raised Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 3rd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Neuphoria Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $21.00.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.